Cumberland wins patent case, brings in promotion of ulcer treatment

Catching up on two recent news items from West End-based Cumberland Pharmaceuticals:

First, the company said an Illinois judge has ruled in its favor in a patent case related to its Acetadote product. Industry giant Mylan Labs and other companies had challenged Cumberland’s patent to a new formulation of Acetadote but the court granted the local company its patent through the summer of 2025 and issued a permanent injunction preventing other firms from marketing a generic version of Acetadote until then.

Separately, Cumberland executives have ended their relationship with Pernix Therapeutics, which had been handling parts of the supply chain, sales and promotion of Cumberland’s Omeclamox-Pak treatment for H. pylori infections and other ulcer diseases. Instead, Cumberland will now work with Gastro-Entero Logic — which helped develop Omeclamox-Pak and get regulatory approval for the treatment — and bring the drug’s promotion work in house.

Nov 24, 2015 2:45 PM

Earnings wrap: Acadia, Cumberland

Behavioral health player beats on revenue, EPS; drug developer's shares climb after hours
Nov 4, 2015 6:50 AM

CET partners with Indian pharmaceutical company

Piramal to manufacture chemicals for joint initiative
Oct 21, 2015 7:08 AM

Cumberland Pharmaceuticals CFO stepping down

CEO to take on financial role as former Crowe Horwath pro transitions to new company
Oct 5, 2015 1:15 PM

Cumberland Pharmaceuticals inks deal with British company

Drug marketers to assist in mutual geographic expansions
Sep 18, 2015 7:09 AM

Cumberland Pharmaceuticals wins case against drug manufacturer

Arbitrator rules Mylan must exclusively produce Acetadote for local company
Sep 17, 2015 7:16 AM

Earnings wrap: Brookdale, Cumberland

Senior living giant cuts guidance; drug marketer's profits slip on lower sales
Aug 5, 2015 2:12 PM

InvisionHeart joins CET Life Sciences Center

Cardiac technology company InvisionHeart is the newest tenant at the CET Life Sciences Center, a partnership between Cumberland Pharmaceuticals, Vanderbilt University and the state of Tennessee.

"We are very pleased to welcome InvisionHeart to the growing community of health care entrepreneurs at the CET Life Sciences Center," A.J. Kazimi, Cumberland Pharmaceuticals CEO, said in a release. "We are committed to helping build the biomedical segment of the health care industry in Middle Tennessee."

InvisionHeart raised $1.9 million last year and most recently hired Melanie Varin, formerly with GE Healthcare, to lead commercialization efforts. The company's devices allow health care providers to read and transmit real-time electrocardiogram tracings to cardiologists. The company is the sixth tenant at the CET Life Sciences Center.

"We are delighted to join the community of companies at the CET Life Sciences Center,” said Josh Nickols, President and CEO of InvisionHeart. “Our office is a great fit for the needs of a collaborative, team-oriented layout, as well as being suited to the requirements of a controlled manufacturing location. The center is conveniently located near the resources of Vanderbilt University, the Nashville Entrepreneur Center, and other healthcare companies that have supported development of the InvisionHeart ECG technology. This location and the second half of 2015 will be vitally important as we prepare for the introduction of our products to the market."

May 20, 2015 3:00 PM

Earnings wrap: Brookdale, Diversicare, Cumberland

Senior living facility company misses; acquisitions boost skilled nursing provider
May 8, 2015 6:53 AM

Cumberland Pharmaceuticals wraps up '14 in the black

Revenues rise 15%, company updates development pipeline status
Mar 4, 2015 6:51 AM